OpGen Inc (OPGN)

[chillswills37]

Cutting edge, genius biotechnologies, but the wrong person as CEO? At this point, if Schacht resigned, most retail shareholders would likely celebrate. Arguably, his departure would open the door to many buyers who also perceive Shacht, with no science background, as a liability if not a leech. Calls by dissatisfied shareholders for his resignation are mushrooming across cyberspace. Opgen, the 3-in-1 company (Curetis, Ares Genetics, OpGen, Inc.) is worth many, many millions, but its premium value has not been unlocked by this rather self-serving glib CEO who lives apart from hoi poloi in insulated luxury courtesy of stockholders. Over a million dollars per year compensation quite undeserved.

1) On Wednesday 01 April 2020, Schacht took over the reins from CEO Evan Jones. On 31 March 2020, OPGN shares closed at $2.55 with a high of $2.70. Market cap on April 3, 2020 was $35.95MM.

2) Three years later, 25 April 2022, OPGN share price stands at US$0.605; market cap US$29.8MM.

3) If CEO performance were judged by those metrics, Schacht is not only a failure, but a pariah whose 2020 compensation package totaled US$1,121,158 (twice that of former CEO Evan Jones).

Don't forget to vote before the upcoming meeting of shareholders.